吴纯刚+龙生勇+刘有贵+李晓

摘 要 目的：比较莫西沙星与依替米星治疗下呼吸道革兰阴性菌感染的疗效和安全性。方法：选择2012年6月至2013年6月收治的下呼吸道革兰阴性菌感染患者64例，按随机数字法分成莫西沙星组32例和依替米星组32例，分别静脉滴注莫西沙星400 mg/d和依替米星100 mg/12 h，共5～10 d，比较两组治疗有效率、细菌清除率及不良反应。结果：莫西沙星组和依替米星组的有效率分别为87.5%（28/32）和90.6%（29/32），细菌清除率分别为87.5%（21/24）和83.33%（20/24），不良反应发生率分别为6.25%（2/32）和3.12%（1/32），组间差异无统计学意义（P>0.05）。结论：莫西沙星和依替米星均是治疗下呼吸道革兰阴性菌感染的有效且安全的抗生素，临床上应个体化选择应用。

关键词 呼吸道感染 莫西沙星 依替米星 临床疗效 安全性

中图分类号：R453.2/R563 文献标识码：A 文章编号：1006-1533（2016）06-0032-03

Comparative study of moxifloxacin and etimicin in the treatment of 32 cases of the lower respiratory tract infection

WU Chungang， LONG Shengyong， LIU Yonggui， LI Xiao

（1.Department of Internal Medicine of the First Peoples Hospital of Changde， Hunan Province， Changde 415003， China；

2.Department of Respiration of Zhonghe Hospital of Wuling District， Changde， Hunan Province， Changde 415003， China）

ABSTRACT Objective： To compare the efficacy and safety of moxifloxacin and etimicin in the treatment of the gram negative bacterial infection in the lower respiratory tract. Methods： From June 2012 to June 2013， 64 cases with the gram negative bacterial infection in the lower respiratory tract were selected and divided into a moxifloxacin group and an etimicin one with 32 cases each according to the random number method. They were given the intravenous infusion of moxifloxacin at 400 mg/d and etimicin at 100 mg/12 h， and 5～10 days in total. The effective rate， bacterial clearance rate and adverse reactions were compared between the two groups. Results： In the moxifloxacin group and the etimicin one， the effective rates were 87.5%（28/32） and 90.6%（29/32）， the bacteriological clearance rates 87.5% and 83.33% and the incidence of adverse reactions 6.25%（2/32） and 3.12%（1/32）， respectively. The differences had no statistical significance between the two groups（P>0.05）. Conclusion： Both moxifloxacin and etimicin are the effective and safe antibiotics in the treatment of the gram negative bacterial infection in the lower respiratory tract， which should be selected and applied individually in clinic.

KEY WORD respiratory tract infection； moxifloxacin； etimicin； clinical treatment effect； safety

莫西沙星是广谱和具有抗菌活性的8-甲氧基氟喹诺酮类抗菌药物。硫酸依替米星是新的半合成氨基糖苷类抗生素。本文对比分析莫西沙星和依替米星治疗下呼吸道革兰阴性菌感染的安全性和有效性。

1 资料和方法

1.1 一般资料

选择我院2012年6月至2013年6月收治的下呼吸道感染住院患者64例，其中男29例，女35例，年龄（58.6±13.2）岁，均经临床表现、实验室检查、肺部CT等影像学检查和细菌培养确诊。按随机数字法将患者分为观察组（莫西沙星组）32例和对照组（依替米星组）32例。两组性别、年龄、体重、给药前体温升高例数及病种等差异均无统计学意义（P>0.05）。

1.2 方法

观察组静脉滴注盐酸莫西沙星（德国拜耳先灵医药保健股份公司）400 mg/ d，疗程5～10 d。对……